vTv Therapeutics Announces Sale Of Shares In Reneo Pharmaceuticals For Proceeds Of $4.4M
Portfolio Pulse from Benzinga Newsdesk
vTv Therapeutics Inc. (NASDAQ:VTVT) has sold all of its common stock in Reneo Pharmaceuticals for approximately $4.4 million. The proceeds will support vTv's preparations for the launch of the cadisegliatin Phase 3 program in type 1 diabetes. vTv remains eligible to receive up to $94.5 million in milestones, as well as royalties on potential sales of products under the Reneo license agreement.
November 01, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
vTv Therapeutics has sold its Reneo Pharmaceuticals stock for $4.4 million, which will support its cadisegliatin Phase 3 program. The company could receive up to $94.5 million in milestones and royalties under the Reneo license agreement.
The sale of Reneo Pharmaceuticals stock provides vTv Therapeutics with financial support for its cadisegliatin Phase 3 program. The potential for additional income from milestones and royalties under the Reneo license agreement could also positively impact the company's financial position and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100